Ligand Pharmaceuticals Inc

NASDAQ:LGNDUnited States

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

Contact Information

Headquarters

555 Heritage Drive, Suite 200JUPITER, FL, United States 33458

Phone

858-550-7500

Fax

302-636-5454

Executives

Non-Executive Independent Chairman of the Board

John Kozarich

President, Chief Operating Officer

Matthew Korenberg

Chief Executive Officer, Director

Todd Davis

Chief Financial Officer

Octavio Espinoza

Chief Legal Officer

Andrew Reardon